Evidence map›Paper›PMID 39017837›Full record

ReviewAdvances in experimental medicine and biology2024

MYB: A Key Transcription Factor in the Hematopoietic System Subject to Many Levels of Control.

Roza Berhanu Lemma, Bettina Maria Fuglerud, Jon Frampton, Odd Stokke Gabrielsen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Roza Berhanu LemmaDepartment of Biosciences, University of Oslo, Oslo, Norway.
Bettina Maria FuglerudDepartment of Biosciences, University of Oslo, Oslo, Norway.
Jon FramptonDepartment of Cancer & Genomic Sciences, College of Medicine & Health, University of Birmingham, Edgbaston, Birmingham, UK.
Odd Stokke GabrielsenDepartment of Biosciences, University of Oslo, Oslo, Norway. o.s.gabrielsen@ibv.uio.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MYB is a master regulator and pioneer factor highly expressed in hematopoietic progenitor cells (HPCs) where it contributes to the reprogramming processes operating during hematopoietic development. MYB plays a complex role being involved in several lineages of the hematopoietic system. At the molecular level, the MYB gene is subject to intricate regulation at many levels through several enhancer and promoter elements, through transcriptional elongation control, as well as post-transcriptional regulation. The protein is modulated by post-translational modifications (PTMs) such as SUMOylation restricting the expression of its downstream targets. Together with a range of interaction partners, cooperating transcription factors (TFs) and epigenetic regulators, MYB orchestrates a fine-tuned symphony of genes expressed during various stages of haematopoiesis. At the same time, the complex MYB system is vulnerable, being a target for unbalanced control and cancer development.

Indexed as

HematopoiesisHematopoietic Stem CellsProto-Oncogene Proteins c-mybAnimalsEpigenesis, GeneticGene Expression RegulationHumansProtein Processing, Post-TranslationalMYB protein, humanProto-Oncogene Proteins c-mybc-MybEnhancerEpigenetic regulatorMYBPioneer factorSUMOTarget genesTranscription factor

Identifiers

PMID39017837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.